🇺🇸 FDA

Company profile · Sponsor

Oncopeptides

Oncopeptides AB (publ)

E9F4EB8 · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

Oncopeptides (E9F4EB8) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E9F4EB8
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. Melflufen

    Oncopeptides

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  2. A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

    Oncopeptides

    Recurrent glioblastoma

    phase 1 other active

    1 trial

Frequently asked questions

What is Oncopeptides?

Oncopeptides (E9F4EB8) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Oncopeptides sponsor?

We track 2 ClinicalTrials.gov-linked programs for Oncopeptides, including Melflufen and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Oncopeptides company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.